Day One Biopharmaceuticals (DAWN) is set to present new follow-up data from its registrational FIREFLY-1 trial of OJEMDA (tovorafenib) at the 30th Annual Meeting & Education Day of the Society for Neuro-Oncology on November 23, 2025.
OJEMDA received accelerated FDA approval last April for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (pLGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.
The data to be presented will include results with more than 36-months follow up from the pivotal Phase 2 FIREFLY-1 trial evaluating OJEMDA (Tovorafenib) as once-weekly oral monotherapy in patients aged 6 months to 25 years with relapsed or progressive pediatric Low-Grade Glioma (pLGG) harboring a known activating BRAF alteration.
OJEMDA has been a key revenue driver for Day One. During the third quarter of 2025, the drug generated $38.5 million in net product revenue, marking a 15% increase from the previous quarter.
For full year 2025, OJEMDA is expected to generate net product revenue between $145 million and $150 million.
DAWN has traded in the range of $5.64 to $15.91 over the past year. The stock closed yesterday's trading at $10.16, up 4.42%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.